BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 29692250)

  • 1. Critical Role of Dipeptidyl Peptidase IV: A Therapeutic Target for Diabetes and Cancer.
    De S; Banerjee S; Kumar SKA; Paira P
    Mini Rev Med Chem; 2019; 19(2):88-97. PubMed ID: 29692250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel DPP-4 inhibitors against diabetes.
    Liu Y; Hu Y
    Future Med Chem; 2014 May; 6(7):793-808. PubMed ID: 24941873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
    Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation.
    Meduru H; Wang YT; Tsai JJ; Chen YC
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides.
    Sivaraman SA; Sabareesh V
    Curr Protein Pept Sci; 2024; 25(4):267-285. PubMed ID: 38173201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
    Bae EJ
    Arch Pharm Res; 2016 Aug; 39(8):1114-28. PubMed ID: 27502601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
    Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
    Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
    Juillerat-Jeanneret L
    J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plant dipeptidyl peptidase-IV inhibitors as antidiabetic agents: a brief review.
    Turdu G; Gao H; Jiang Y; Kabas M
    Future Med Chem; 2018 May; 10(10):1229-1239. PubMed ID: 29749760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.
    Singh AK; Jatwa R; Purohit A; Ram H
    J Asian Nat Prod Res; 2017 Oct; 19(10):1036-1045. PubMed ID: 28351157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Research Progress of DPP-4 Inhibitors.
    Sun ZG; Li ZN; Zhu HL
    Mini Rev Med Chem; 2020; 20(17):1709-1718. PubMed ID: 32600230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes.
    Deacon CF
    Peptides; 2018 Feb; 100():150-157. PubMed ID: 29412814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.
    Omar B; Ahrén B
    Diabetes; 2014 Jul; 63(7):2196-202. PubMed ID: 24962916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS; Srinivasan BP; Gandhi S
    Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent patents of dipeptidyl peptidase IV inhibitors.
    Mendieta L; Tarrago T; Giralt E
    Expert Opin Ther Pat; 2011 Nov; 21(11):1693-741. PubMed ID: 22017411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.